Dr. Jaume CapdevilaDr. Jaume Capdevila

Jaume Capdevila Castillon

FACULTATIU ESPECIALISTA ONCOLOGIA MÈDICA

Dades destacades

  • A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).

Dades del professional

Centro Médico Teknon
FACULTATIU ESPECIALISTA ONCOLOGIA MÈDICA
Juliol 2023 - Actualitat
Hospital Universitario de La Plana
Facultatiu/iva esp.
Gener 2008 - Gener 2008
Hospital Universitari Vall D'Hebron
Facultatiu/iva esp.
Gener 2006 - Actualitat
Hospital de La Santa Creu I Sant Pau
Metge Resident
Gener 2006 - Gener 2006
Estudi
Llicenciat en Medicina i Cirurgia
universitat, Universidad de Lleida
2001
Formació Sanitària Especialitzada
Oncologia Mèdica
hospital
Una altra titulació
Beca al Departament d'Oncologia Endocrina
hospital
Una altra titulació
Fellowship al Departament de Bioquímica i Biologia Molecular
universitat
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).
Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Govt
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies.
Journal Article
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.
Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Govt
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study.
Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Govt
Hypoxia Inducible factor 2 alpha (HIF2a) inhibitors: targeting genetically driven tumor hypoxia.
Journal Article
Increased progression-free survival with cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer irrespective of prior VEGFR-targeted therapy and tumor histology: a subgroup analysis of the COSMIC-311 study.
Journal Article
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer.
Journal Article, Review
Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS).
Journal Article, Multicenter Study, Observational Study
Streptozotocin, 1982-2022: Forty Years from the FDAs Approval to Treat Pancreatic Neuroendocrine Tumors.
Journal Article, Review
Total neoadjuvant therapy with or without aflibercept in rectal cancer: Three-year results of GEMCAD-1402.
Journal Article
Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice.
Journal Article, Research Support, Non-U.S. Govt
Demana cita amb aquest professional